Morgan Stanley Call 28.5 VNA 19.1.../ DE000MG20F41 /
30/05/2024 08:58:47 | Var.-0.010 | Denaro12:42:45 | Lettera12:42:45 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.450EUR | -2.17% | 0.460 Quantità in denaro: 250,000 |
0.470 Quantità in lettera: 250,000 |
VONOVIA SE NA O.N. | 28.50 EUR | 19/12/2025 | Call |
GlobeNewswire
13:00
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment ...
GlobeNewswire
13:00
Troilus Discovers New At-Surface Gold Zone ‘West Rim’ With Intercept of 1.37 g/t AuEq Over 11m Withi...
GlobeNewswire
13:00
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conf...
GlobeNewswire
13:00
Beamr Cloud upgrade for enterprises: customizable video service with enhanced security and privacy
GlobeNewswire
13:00
Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research
GlobeNewswire
13:00
SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
GlobeNewswire
13:00
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis ...
GlobeNewswire
13:00
17 Education & Technology Group Inc. to Report First Quarter 2024 Unaudited Financial Results on Jun...
GlobeNewswire
13:00
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and P...
GlobeNewswire
13:00
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Trea...
GlobeNewswire
13:00
Rivalry Reports First Quarter 2024 Results, Expands Into Crypto Segment Through Rivalry Token
GlobeNewswire
13:00
Virtu Financial, Inc. Announces Investor Meetings for Potential Opportunistic Offering of Senior Sec...